Catalent to Acquire Metrics Contract Services for $475 Million to Expand Oral and High-Potent CDMO Capabilities

Codis Acquires Catalent’s Nottingham (UK) Facility

July 6, 2026

Healthcare Services

Codis has agreed to acquire Catalent Pharma Solutions’ spray-drying and oral solid dose facility in Nottingham, United Kingdom. The deal is expected to close in Q3 2026 (subject to customary conditions) and will add oral solid dose (OSD) development and small-scale commercial manufacturing to Codis’ existing large-scale commercial spray-drying site in Haverhill.

Novo Holdings Acquires Catalent for $16.5 Billion

December 18, 2024

Healthcare Services

Novo Holdings A/S agreed to acquire Catalent, Inc. in an all-cash transaction valued at approximately $16.5 billion ($63.50 per share). The deal was later completed, and Catalent became a private company under Novo Holdings ownership; Novo Nordisk subsequently acquired Catalent’s three fill-finish sites in Italy, Indiana (USA), and Belgium.

Ardena Acquires Catalent's Somerset, New Jersey Drug Product Facility

October 14, 2024

Pharmaceuticals

Ardena, a GHO Capital-backed CDMO, has signed a definitive agreement to acquire Catalent's FDA-approved drug product manufacturing facility in Somerset, New Jersey. The acquisition — expected to close in early 2025 subject to approvals — expands Ardena's US footprint and downstream capabilities in oral solid dosage manufacturing and bioanalytical services.

Pace Life Sciences Acquires Catalent's RTP Small-Molecule Analytical Services Laboratory

September 26, 2024

Healthcare Services

Pace Life Sciences, a PE-backed CDMO, has acquired Catalent’s Center-of-Excellence for Small Molecule Analytical Services located in Research Triangle Park, North Carolina. The acquisition expands Pace Life Sciences’ national analytical testing network (to nine sites) and strengthens its small- and large-molecule analytical capabilities to support biopharma clients; Catalent sold the site as part of its portfolio adjustments.

Catalent Acquires Bettera Brands from Highlander Partners for $1 Billion

August 30, 2021

Food & Beverage

Catalent, Inc. agreed to acquire Bettera Holdings, LLC (Bettera Brands) from Highlander Partners for $1 billion. The acquisition expands Catalent's consumer health and nutraceutical manufacturing capabilities—adding Bettera's gummy, soft chew, and lozenge production capacity and approximately 500 employees across four U.S. facilities.

Catalent Acquires Paragon Bioservices for $1.2 Billion

May 20, 2019

Biotechnology

Catalent, Inc. completed the $1.2 billion acquisition of Paragon Bioservices, Inc., a viral vector development and manufacturing partner for gene therapies, expanding Catalent’s biologics and gene therapy capabilities. Paragon’s Baltimore-area facilities and ~380 employees will join Catalent’s global biologics platform, while Catalent secured financing including incremental term loans and a convertible preferred issuance to Leonard Green & Partners to support the transaction.